Table. 1 Phenotypic characteristics of UTIs and DRC isolates of E. faecalis
From: Role of CRISPR-Cas system on antibiotic resistance patterns of Enterococcus faecalis
Antibiotics | Total resistant isolates (%) | UTI resistant isolates (%) | DRC resistant isolates (%) | p-value |
|---|---|---|---|---|
Ampicillin | 10 (6.94 %) | 7 (9.33 %) | 3 (4.34 %) | 0.199 |
Penicillin | 33 (22.92 %) | 30 (40.00 %) | 3 (4.35 %) | < 0.001 |
Vancomycin | 10 (6.94 %) | 8 (10.67 %) | 2 (2.90 %) | 0.064 |
Teicoplanin | 11 (7.64 %) | 9 (12.00 %) | 2 (2.90 %) | 0.038 |
Fosfomycin | 28 (19.44 %) | 17 (22.67 %) | 11 (15.94 %) | 0.210 |
Erythromycin | 70 (48.61 %) | 62 (82.67 %) | 8 (11.60 %) | < 0.001 |
Linezolid | 2 (1.38 %) | 2 (2.67 %) | 0 | 0.270 |
Tetracycline | 87 (60.42 %) | 68 (90.67 %) | 19 (27.54 %) | < 0.001 |
Ciprofloxacin | 65 (45.14 %) | 49 (65.33 %) | 16 (23.20 %) | < 0.001 |
Gentamicin (128 µg) | 49 (34.03 %) | 41 (54.67 %) | 8 (11.60 %) | < 0.001 |
Rifampin | 99 (68.75 %) | 49 (65.33 %) | 50 (72.47 %) | 0.229 |